Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

被引：2
|
作者：
Kalff, Anna
Kennedy, Nola
Smiley, Angela
Prince, H. Miles
Roberts, Andrew W.
Bradstock, Kenneth F.
Lourenco, Richard De Abreu
Spencer, Andrew
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.537.537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
537
引用
收藏
页数：2
相关论文
共 29 条
  • [21] Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk
    Yong, Kwee
    Wilson, William
    Camilleri, Marquita
    Ramasamy, Karthik
    Streetly, Matthew
    Sive, Jonathan
    Bygrave, Ceri A.
    Chapman, Michael
    de Tute, Ruth M.
    Chavda, Selina J.
    Phillips, Elizabeth H.
    Cuadrado, Maria del Mar
    Pang, Gavin
    Jenner, Richard
    Dadaga, Tushhar
    Kamora, Sumaiya
    Cavenagh, James
    Clifton-Hadley, Laura
    Owen, Roger G.
    Popat, Rakesh
    BLOOD, 2021, 138
  • [22] Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.
    Jagannath, Sundar
    Abonour, Rafat
    Durie, Brian G.
    Shah, Jatin J.
    Narang, Mohit
    Terebelo, Howard R.
    Gasparetto, Cristina
    Toomey, Kathleen
    Hardin, James W.
    Wagner, Lynne I.
    Agarwal, Amit
    Srinivasan, Shankar
    Kitali, Amani
    Zafar, Faiza
    Sturniolo, Michael
    Rifkin, Robert M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
    Alina Striha
    A. John Ashcroft
    Anna Hockaday
    David A. Cairns
    Karen Boardman
    Gwen Jacques
    Cathy Williams
    John A. Snowden
    Mamta Garg
    Jamie Cavenagh
    Kwee Yong
    Mark T. Drayson
    Roger Owen
    Mark Cook
    Gordon Cook
    Trials, 19
  • [24] The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
    Striha, Alina
    Ashcroft, A. John
    Hockaday, Anna
    Cairns, David A.
    Boardman, Karen
    Jacques, Gwen
    Williams, Cathy
    Snowden, John A.
    Garg, Mamta
    Cavenagh, Jamie
    Yong, Kwee
    Drayson, Mark T.
    Owen, Roger
    Cook, Mark
    Cook, Gordon
    TRIALS, 2018, 19
  • [25] EXPOSURE-SAFETY-EFFICACY ANALYSIS OF ORAL IXAZOMIB CITRATE (MLN9708) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): PHASE 3 DOSE SELECTION FOR MAINTENANCE POST AUTOLOGOUS STEM CELL TRANSPLANT
    Gupta, N.
    Labotka, R.
    Liu, G.
    Hui, A. M.
    Venkatakrishnan, K.
    HAEMATOLOGICA, 2014, 99 : 364 - 364
  • [26] Engraftment post melphalan autologous stem cell transplant (ASCT) for multiple myeloma (MM): Granulocyte colony stimulating factor (G-CSF) initiation correlates with neutrophil recovery independent of CD34 dose: a study from 3 United Kingdom Centres
    Krishna, R.
    Abhishekh, H. A.
    Brown, R.
    Qadir, D.
    Ellis, V.
    Ardern, C.
    Drake, A.
    Sjursen, A.
    Thachil, J.
    Saif, M.
    Dignan, F.
    Willis, F.
    Bloor, A.
    Koh, M.
    Klammer, M.
    Cavet, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 95 - 95
  • [27] Influenza (flu) Vaccine Administration to Patients with Multiple Myeloma (MM) Prior to Autologous T-Cell Harvest Leads to Better Reconstitution of Flu Immunity After High Dose Melphalan and Autologous Stem Cell Transplant (ASCT) and Reinfusion of Primed Ex-Vivo Co-Stimulated Autologous T-Cells and Post-ASCT Second Flu Vaccination Than Post-ASCT Flu Vaccination Alone
    Stadtmauer, Edward A.
    Vogl, Dan T.
    Aqui, Nicole A.
    Rapoport, Aaron P.
    Macdonald, Kenyetta
    Murphy, Heather
    Bhagat, Rita
    Mangan, Patricia A.
    Chew, Anne
    Veloso, Elizabeth
    Levine, Bruce
    Vonderheide, Robert H.
    June, Carl H.
    Sullivan, Kathleen
    BLOOD, 2009, 114 (22) : 329 - 330
  • [28] ADOPTIVE TRANSFER OF GENE-MODIFIED T-CELLS ENGINEERED TO EXPRESS HIGH-AFFINITY TCR'S FOR CANCER-TESTIS ANTIGENS NY-ESO-1 OR LAGE-1, IN MULTIPLE MYELOMA (MM) PATIENTS POST AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT (ASCT)
    Levine, B. L.
    Rapoport, A. P.
    Stadtmauer, E. A.
    Vogl, D. T.
    Weiss, B.
    Binder-Scholl, G. K.
    Smethurst, D. P.
    Brewer, J. E.
    Bennett, A. D.
    Gerry, A. B.
    Pumphrey, N. J.
    Tayton-Martin, H. K.
    Ribiero, L.
    Veloso, E. A.
    Finklestein, J.
    Kulikovskaya, I.
    Gupta, M.
    Suppa, E.
    Mikheeva, T.
    Zheng, Z.
    Brennan, A. L.
    Bersenev, A.
    Tripic, T.
    Cribioli, E.
    Cotte, J.
    Badros, A. Z.
    Yanovich, S.
    Akpek, G.
    McConville, H.
    Kerr, N.
    Philip, S.
    Betts, K.
    Westphal, S.
    Kalos, M.
    Jacobsen, B. K.
    June, C. H.
    CYTOTHERAPY, 2013, 15 (04) : S13 - S13
  • [29] Phase III Study of Daratumumab/rhuph20 (nsc-810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803
    Krishnan, Amrita
    Hoering, Antje
    Hari, Parameswaran
    Sexton, Rachael
    Orlowski, Robert Z.
    BLOOD, 2020, 136
123